There is already a drive towards developing drugs that target activated Cdc42 and our findings now indicate that these agents may be useful for the treatment of HPV-related cancers too.
Dr Oliver said: "There are literally hundreds of publications describing the potential role of Cdc42 in malignant disease but our work is the first to show that HPV can activate this protein."